Logos Capital

Logos Capital is a San Francisco-based investment firm that specializes in the biotechnology sector, employing a fundamental, research-driven approach to identify promising opportunities across the healthcare landscape. Founded by Artem Fomenko, the firm is renowned for its deep expertise in life sciences, focusing on companies with innovative therapeutic platforms and strong scientific foundations. Their investment philosophy is rooted in rigorous scientific and clinical due diligence, aiming to support companies that are poised to make significant advancements in treating diseases.

Logos Capital's investment strategy encompasses both public and private equities, making it a prominent "crossover" investor within the biotech space. This dual approach allows them to engage with companies from their late-stage private development through their journey in the public markets. They are particularly interested in companies developing novel drug candidates and technologies across various therapeutic areas, including oncology, immunology, and neurological disorders, often taking significant positions in firms they believe possess high growth potential and strong intellectual property.

With reported assets under management (AUM) often cited in the range of $1.5 billion, Logos Capital is a substantial player in the biotech investment ecosystem. While a significant portion of their capital is allocated to public market positions, their active participation in private funding rounds, particularly late-stage Series C and D rounds, underscores their commitment to fostering growth in innovative private companies. For instance, they notably participated in the $100 million Series B for ReNAgade Therapeutics, demonstrating their capacity to deploy substantial capital into high-potential private ventures. Their typical first checks into private companies generally range from several million dollars up to tens of millions, reflecting their strategy of taking meaningful stakes in companies aligned with their long-term vision.